LAX.SH
HALEOS LABS LIMITED·Healthcare Companies·Pharmaceuticals & Biotechnology Companies
Price
1,465
+0.59%52W Range
Market Cap
₹442.91 Cr
Traded: ₹0.08 Cr (0.02%) 0.0x
Free Float: ₹109.49 Cr (0.08% of FF traded)
Volume · 60D trend
569 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
MTF Exposure Trend
33 sessions · funded amount, % of FF, daily delta
LAX.SH
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| ROE | -- | +8.0% | +8.0% | -- | -- | Stable |
| Sales | -- | +5.0% | +2.0% | -- | -3.0% | Decelerating |
| Return | -- | +22.0% | +44.0% | +15.0% | -- | Stable |
| Profit | -- | +5.0% | +20.0% | -- | -14.0% | Stable |
Quarterly Results
Dec 2022
Sep 2022
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Mar 2026PDF ↗ | Dec 2025PDF ↗ | Sep 2025PDF ↗ | Jun 2025PDF ↗ | Mar 2025PDF ↗ | Dec 2024PDF ↗ | Sep 2024PDF ↗ | Jun 2024PDF ↗ | Mar 2024PDF ↗ | Dec 2023PDF ↗ | Sep 2023PDF ↗ | Jun 2023PDF ↗ | Mar 2023PDF ↗ | Dec 2022 | Sep 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 75 | 95 | 81 | 83 | 89 | 85 | 78 | 93 | 90 | 72 | 69 | 75 | 64 | 88 | 81 |
| Expenses | 71 | 81 | 68 | 71 | 82 | 72 | 70 | 76 | 79 | 63 | 61 | 72 | 61 | 79 | 73 |
| Operating Profit | 4 | 14 | 14 | 12 | 7 | 13 | 9 | 16 | 11 | 9 | 8 | 3 | 2 | 9 | 8 |
| OPM % | 5.5% | 14.8% | 16.7% | 14.2% | 8.3% | 15.1% | 10.9% | 17.6% | 12.6% | 12.9% | 11.4% | 3.4% | 3.6% | 10.6% | 10.2% |
| Other Income | 2 | 0 | 0 | 1 | 2 | 0 | 2 | 0 | 2 | 1 | 0 | 1 | 5 | 0 | 0 |
| Interest | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 2 | 3 | 2 | 2 | 2 | 2 |
| Depreciation | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 3 | 3 | 3 |
| Profit Before Tax | 1 | 9 | 8 | 7 | 4 | 7 | 5 | 11 | 7 | 4 | 2 | -3 | 2 | 6 | 4 |
| Tax % | 62.2% | 24.3% | 24.4% | 37.6% | 11.4% | 29.8% | 29.7% | 33.3% | 8.7% | -8.1% | 126.5% | 40.3% | 10.6% | 31.3% | 23.7% |
| Net Profit | 0 | 7 | 6 | 4 | 3 | 5 | 3 | 7 | 6 | 4 | -0 | -4 | 2 | 4 | 3 |
| Exceptional Items | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 |
| EPS (Rs) | 1.5 | 21.9 | 20.2 | 13.8 | 9.8 | 18.1 | 15.4 | 23.1 | 19.5 | 14.2 | 2.3 | -6.0 | 5.7 | 13.2 | 9.1 |
| Sales Growth (YoY) | -15.7% | 12.0% | 3.7% | -10.9% | -1.0% | 17.4% | 13.3% | 24.0% | 41.2% | -18.4% | -14.8% | -9.3% | -33.4% | -- | -- |
| Sales Growth (QoQ) | -- | 16.5% | -1.4% | -7.4% | 5.3% | 7.8% | -15.2% | 2.8% | 24.9% | 4.0% | -7.2% | 17.1% | -27.8% | 8.7% | -- |
| OP Growth (YoY) | -43.9% | 10.2% | 58.5% | -28.1% | -34.7% | 37.1% | 8.1% | 540.9% | 398.2% | -0.7% | -4.1% | -- | -- | -- | -- |
| OP Growth (QoQ) | -70.4% | 3.5% | 16.0% | 57.8% | -41.8% | 48.8% | -47.4% | 43.3% | 22.2% | 17.3% | 212.2% | 11.4% | -75.7% | 13.3% | -- |
| Profit Growth (YoY) | -85.0% | 21.0% | 31.0% | -41.0% | -50.0% | 27.0% | 587.0% | 489.0% | 562.0% | 8.0% | -75.0% | -160.0% | -78.0% | 71.2% | -37.1% |
| EPS Growth (YoY) | -- | 21.1% | 30.6% | -40.6% | -49.7% | 27.2% | 586.7% | 489.1% | 244.9% | 7.7% | -75.3% | -- | -- | -- | -- |
| EPS Growth (QoQ) | -- | 8.5% | 46.7% | 40.1% | -45.7% | 17.1% | -33.3% | 18.6% | 37.3% | 532.0% | 137.8% | -205.1% | -57.1% | 45.0% | -- |
| OP Margin | -- | 14.8% | 16.7% | 14.2% | 8.3% | 15.1% | 10.9% | 17.6% | 12.6% | 12.9% | 11.4% | 3.4% | 3.6% | 10.6% | 10.2% |
| Net Margin | -- | 7.0% | 7.9% | 5.3% | 3.9% | 5.7% | 4.2% | 7.7% | 7.2% | 5.7% | -0.6% | -5.1% | 3.3% | 4.3% | 3.8% |
| Material Cost % | 41.1% | 46.0% | 38.1% | 42.6% | 44.2% | 42.1% | 45.6% | 46.8% | 48.7% | 43.4% | 46.6% | 58.7% | 49.0% | 56.3% | 56.5% |
| Employee Cost % | 21.5% | 17.6% | 19.9% | 19.8% | 18.5% | 17.3% | 18.0% | 15.5% | 15.0% | 17.4% | 17.7% | 16.6% | 18.0% | 13.0% | 12.6% |
| P/S | 1.27 | 1.37 | 1.13 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/E | 22.31 | 24.08 | 20.38 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/B | 2.07 | 2.32 | 1.85 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Exchange Filings
50Enclosed -- newspaper advertisement for Q1F27 results.
Enclosed - Outcome of 98th Board meeting.
Postal Ballot Notice (30.07.2026 to 28.08.2026)
Enclosed -- RTA certificate.
Intimation of Closure of Trading Window.
Communication to shareholders regarding transfer of shares to the IEPF suspense account for the unclaimed dividend for the year 2018-19.
In lieu of change in Board composition, the Board Committees are reconstituted.
Enclosed - newspaper advertisement for Q4 results.
Enclosed financial results for the quarter and year ended 31st March, 2026.
Enclosed - Annual Secretarial Compliance Report F26
Enclosed are the details related to the appointment of Statutory Auditors and Cost Auditors.
Reappointment of Mrs Sudeepthi Gopineedi as whole-time Director for a further period of 5 years w.e.f. Sept 2, 2026, subject to approval of Shareholders.
Resignation of Mrs. Sundaramma Patilbandla from the post of Independent Director w.e.f. May 29, 2026.
Enclosed - Outcome of 97th Board meeting.
Request shareholders to update their KYC details (reminder no. 6) and information about the second 100-day campaign from April 1, 2026 to July 9, 2026.
Haleos Labs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2026 ,inter alia, to consider and approve the audited financial results (Standalone ....
Credit rating of the Company and its material subsidiary.
Outcome along with Scrutinizers report.
Disclosure related to the non-encumbrance of shares received from promoters.
Enclosed - RTA certificate.
Confirmation received from the erstwhile Promoter group.
Enclosed - newspaper advertisement.
Communication to Shareholders
Postal Ballot Notice (31.03.2026 to 29.04.2026)
Enclosed - events calendar for Postal Ballot.
Intimation of Closure of Trading Window.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for TV Praveen
Special Window for the relodgment of share transfer requests in physical mode.
Enclosed - Outcome of 96th Board meeting.
Haleos Labs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/02/2026 ,inter alia, to consider and approve Unaudited financial results (Standalone ....
Company has entered into Stategic Development collabration with HRV Global Life Sciences Private Limited and will make further disclosure as and when there is any material update on the same.
Enclosed summary from December 1, 2025 to January 6, 2026.
Enclosed - RTA certificate.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for TV Praveen
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for TV Praveen
Intimation of Closure of Trading Window.
Enclosed is summary for the month of November, 2025
Enclosed.
New Scrip id of the Company pursuant to change in name of the Company.
New logo pursuant to change in the name of the Company.
Enclosed - Newspaper advertisement.
Enclosed -- Outcome of 95th Board meeting.
Dividend payable to shareholders who have not updated their KYC details is withheld and shall be released only upon complying with the KYC norms.
Enclosed is the summary for the month of October 2025.
SMS Lifesciences India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/11/2025 ,inter alia, to consider and approve Unaudited financial ....
Enclosed -- RTA certificate.
Enclosed is summary for the month of September 2025.
Voting result of 19th Annual General Meeting.
Summary of proceedings of 19th Annual General Meeting.
Mr. TV Praveen was reappointed as Managing Director in the material subsidiary.
Annual Reports
9Credit Ratings
6Concalls
1Jul 2025
31 Jul 2025